• The CC2C6 antibody recognizes human CD47 and has been shown to be useful for flow cytometry. (biolegend.com)
  • The CC2C6 monoclonal antibody can block the binding of HCD47 antibody to CD47. (biolegend.com)
  • Treatment with a disulfide-linked antibody dimer induces apoptosis of CD47-positive primary B-CLL and leukemic cells (MOLT-4 and JOK-1). (wikipedia.org)
  • Disrupting the binding of CD47 to SIRPα has emerged as a promising immunotherapeutic strategy for advanced cancers by potentiating antibody-dependent cellular phagocytosis (ADCP) of targeted antibodies. (aacrjournals.org)
  • The drug candidate is a monoclonal antibody acts by targeting leukocyte surface antigen CD47. (pharmaceutical-technology.com)
  • Sana's hypoimmune technology seeks to overcome the immunologic rejection of allogeneic cells via disruption of human leukocyte antigen (HLA) class I and class II expression to allow cells to evade the adaptive immune system, including antibody and T cell responses, as well as overexpression of CD47 to allow cells to evade the innate immune cell system, in particular macrophages and natural killer (NK) cells. (pipelinereview.com)
  • Antiviral activities of antibodies may either be dependent only on interactions between the antibody and cognate antigen, as in binding and neutralization of an infectious virion, or instead may require interactions between antibody-antigen immune complexes and immunoproteins or Fc receptor expressing immune effector cells. (frontiersin.org)
  • The Fc receptor-dependent function of antibody-dependent cellular phagocytosis (ADCP) provides mechanisms for clearance of virus and virus-infected cells, as well as for stimulation of downstream adaptive immune responses by facilitating antigen presentation, or by stimulating the secretion of inflammatory mediators. (frontiersin.org)
  • Fc receptor-dependent antibody functions are also involved in activation of downstream adaptive immune responses by facilitating antigen presentation or by stimulating the secretion of inflammatory mediators ( 12 , 13 ). (frontiersin.org)
  • Background AK117 is a humanized monoclonal antibody targeting CD47 which widely expresses on innate immune cells, such as macrophages, and functions as a regulator of phagocytosis. (bmj.com)
  • Hematology toxicity is the major concern of an anti-CD47 antibody. (bmj.com)
  • Raji cells, HT-29 cells, and HL-60 cells which highly express CD47 were used as target cells to evaluate a pro-phagocytic activity of AK117 as a monotherapy or in combination with anti-EGFR antibody, anti-CD20 antibody or azacitidine. (bmj.com)
  • Immunotherapies with antibody-drug-conjugates (ADC) and CAR-T cells, targeted at tumor surface antigens (surfaceome), currently revolutionize clinical oncology. (lu.se)
  • The efficacy was analogous or preferable to the combination of CAR T cells and CD47 antibody. (bvsalud.org)
  • Furthermore, locally delivering anti-CD47 by CAR T cells potentially limits toxicities relevant to systemic antibody treatment. (bvsalud.org)
  • Context: Magrolimab is an antibody blocking CD47, a "don't eat me" signal expressed on cancer cells, to escape immune surveillance and macrophage-mediated clearance. (ox.ac.uk)
  • The efficacy of a therapeutic antibody depends on the Fab fragment and its binding activity to the target antigen, but also depends on the Fc fragment and its interaction with key Fc receptors.Therefore, candidates must be tested against a panel of receptors during antibody engineering. (acrobiosystems.com)
  • In several different atherosclerotic model mice, blocking CD47 with anti-CD47 antibody significantly reduced accumulation of arterial plaque. (edu.pl)
  • An atherosclerotic-model antibody, the anti-CD47 antibody, was sorbed onto the particle surfaces in water and phosphate-buffered saline (PBS) for 4 h. (edu.pl)
  • 1 However, how to use CD47 antibody to achieve effective drug delivery remains a key issue to be solved in future research. (edu.pl)
  • SAN DIEGO and SUZHOU, China, December 13, 2021 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). (adagene.com)
  • Our novel anti-CD47 antibody and CD20xCD3 bispecific TCE programs successfully leverage SAFEbody technology for precision masking to decouple efficacy from the toxicities that are often associated with therapeutic modalities for these two important targets on the forefront of clinical development for hematologic malignancies," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. (adagene.com)
  • ADG153-G4 parental antibody and its activated SAFEbody can block the CD47 signal by targeting a unique epitope of CD47 with high affinity and minimal RBC hemagglutination. (adagene.com)
  • This agreement will see InnoBation Bio develop and manufacture clinical trial sample substances of an anti-CD47 antibody. (asiabiotech.com)
  • GenScript ProBio, a global biopharmaceutical contract development and manufacturing organisation (CDMO), announced on January 26th, 2022 that it entered into a contract with InnoBation Bio to develop and manufacture clinical trial sample substances of an anti-CD47 antibody, which is to be used as an Immune Checkpoint Inhibitor (ICI). (asiabiotech.com)
  • InnoBation Bio, led by Seung-gu Kim (CEO), is a biopharmaceutical company specialising in the development of biomarkers, Chimeric Antigen Receptor (CAR) T cell therapy agents, and antibody-based anti-cancer therapeutics. (asiabiotech.com)
  • Based on this latest agreement with GenScript ProBio, InnoBation Bio is planning to develop a stable cell line for an anti-CD47 antibody production. (asiabiotech.com)
  • As such, numerous large-scale pharmaceutical companies have high expectations of an anti-CD47 antibody. (asiabiotech.com)
  • IBA-101, a next-generation anti-CD47 antibody developed by InnoBation Bio solves this anaemia-related problem of existing anti-CD47 antibodies by virtue of its RBCs sparing property. (asiabiotech.com)
  • CD47 also known as Rh-associated protein, gp42, integrin-associated protein (IAP), and neurophilin, is a 42-52 kD member of the immunoglobulin superfamily containing a five-pass transmembrane attachment. (biolegend.com)
  • CD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. (wikipedia.org)
  • CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα). (wikipedia.org)
  • CD47 interacts with signal-regulatory protein alpha (SIRPα), an inhibitory transmembrane receptor present on myeloid cells. (wikipedia.org)
  • The long 3' UTR of CD47 enables efficient cell surface expression of CD47 protein, whereas the short 3' UTR primarily localizes CD47 protein to the endoplasmic reticulum. (nih.gov)
  • CD47 protein localization occurs post-translationally and independently of RNA localization. (nih.gov)
  • In our model of 3' UTR-dependent protein localization, the long 3' UTR of CD47 acts as a scaffold to recruit a protein complex containing the RNA-binding protein HuR (also known as ELAVL1) and SET to the site of translation. (nih.gov)
  • We also show that CD47 protein has different functions depending on whether it was generated by the short or long 3' UTR isoforms. (nih.gov)
  • CD47 ( C luster of D ifferentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene . (wikidoc.org)
  • SIRPγ (CD172g) binds to CD47 (integrin-associated protein/IAP) that is widely expressed on most hematopoietic cells, epithelial cells, endothelial cells, fibroblasts and many tumor cell lines. (bdbiosciences.com)
  • The researchers will work with the CD47 protein. (sarcomahelp.org)
  • They have previously shown in an LMS mouse model that inhibiting the CD47 protein allows immune cells called macrophages to more effectively destroy LMS cells. (sarcomahelp.org)
  • The glycoprotein CD47 (integrin-associated protein, IAP) is present on the surface of virtually all cells, including red blood cells (RBCs). (ashpublications.org)
  • CD47 acts like a marker of self by ligating the macrophage inhibitory receptor signal regulatory protein α (SIRPα). (ashpublications.org)
  • As proof-of-concept, the established target antigen CD44 was identified as a commonly and abundantly expressed surface protein with high endocytic activity. (lu.se)
  • Simultaneously, RRX-001 reduces CD47 protein levels, aiding in preventing immune escape by calreticulin-rich cancer cells. (bvsalud.org)
  • A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN . (nih.gov)
  • New data indicate that CXCR4 interacts with the surface protein CD47 in a novel form of immunosurveillance, called ImmunoGenic Surrender (IGS). (unisr.it)
  • The researchers integrated the protein CD47 into the surface of lentiviral vectors (LVs) so they could escape detection and destruction by the immune system. (international-biopharma.com)
  • The CD47 protein is known to inhibit this destructive process, so San Raffaele Telethon Institute for Gene Therapy scientific director Luigi Naldini and colleagues hypothesized that attaching CD47 to LV could help gene therapies escape macrophages. (international-biopharma.com)
  • CD47 is an essential type of protein that protects normal cells in the human body from being attacked by the immune system. (asiabiotech.com)
  • Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. (exbio.cz)
  • Manufacture of chimeric antigen receptor (CAR)-T cells usually involves the use of viral delivery systems to achieve high transgene expression. (cartherics.com)
  • A high recurrence rate of non-Hodgkin's lymphoma (NHL) following chimeric antigen receptor T (CAR T) cell treatment remains a bottleneck, and immunosuppressive tumor microenvironment (TME) compromising CAR T cell efficacy in NHL is the primary cause of relapse. (bvsalud.org)
  • CD47 functions as an adhesion molecule and thrombospondin receptor and is non-covalently associated with β3 integrins CD51/CD61, CD41/CD61. (biolegend.com)
  • CD47 is a 50 kDa membrane receptor that has extracellular N-terminal IgV domain, five transmembrane domains, and a short C-terminal intracellular tail. (wikipedia.org)
  • CD47 is a high affinity receptor for thrombospondin-1 (TSP-1), a secreted glycoprotein that plays a role in vascular development and angiogenesis, and in this later capacity the TSP1-CD47 interaction inhibits nitric oxide signaling at multiple levels in vascular cells. (wikipedia.org)
  • SIRPα-Fc-CD40L bound CD47 and CD40 with high affinity and activated CD40 signaling in the absence of Fc receptor cross-linking. (aacrjournals.org)
  • CD47 serves as the ligand for a receptor on these innate immune cells, SIRPα, which in turn delivers an inhibitory signal for phagocytosis. (bmj.com)
  • Here we report that the reverse signaling using CD47 as a receptor additionally enhances a pro-survival function of prostate cancer cells under phagocytic attack. (bvsalud.org)
  • CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. (abeomics.com)
  • CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. (abeomics.com)
  • The CD47/SIRPα interaction leads to bidirectional signaling, resulting in different cell-to-cell responses including inhibition of phagocytosis, stimulation of cell-cell fusion, and T-cell activation. (wikipedia.org)
  • Murine SIRPα-Fc-CD40L outperformed CD47 blocking and CD40 agonist antibodies in murine CT26 tumor models and synergized with immune checkpoint blockade of PD-1 and CTLA4. (aacrjournals.org)
  • These data illustrated that whereas CD47/SIRPα inhibition could potentiate tumor cell phagocytosis, CD40-mediated activation of a type I interferon response provided a bridge between macrophage- and T-cell-mediated immunity that significantly enhanced durable tumor control and rejection. (aacrjournals.org)
  • The CD47/SIRPα pathway is an endogenous pathway that facilitates clearance of aged or dying cells ( 1 ). (aacrjournals.org)
  • The antiphagocytic activity of CD47/SIRPα serves as a macrophage checkpoint or "do not eat me" signal ( 1 ). (aacrjournals.org)
  • SIRPγ (CD172g) may play a regulatory role in T cell-T cell interactions and may induce apoptosis through CD47. (bdbiosciences.com)
  • CD47 is overexpressed on many cancer cells and binds SIRPα on immune phagocytic cells to produce a "don't eat me" signal. (pharmiweb.com)
  • Methods Activity of AK117 binding to CD47 to block the interaction between CD47 and SIRPα were determined by FACS, and binding of AK117 to human RBC was also evaluated. (bmj.com)
  • Results AK117 could effectively binds to CD47, and competes with SIRPα for binding to the antigen on Raji cells (figure 1). (bmj.com)
  • B) FACS competitive binding curve of AK117 and Hu5F9-G4 with SIRPαECD-mFc to CD47 on raji cells. (bmj.com)
  • Co-ligation of SIRPα with CD47 abrogates nanocluster segregation. (ox.ac.uk)
  • The company's SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. (canadianinsider.com)
  • As an agent targeting CD47 being investigated as an anti-tumor therapeutic, AK117 is engineered on a human IgG4 scaffold to minimize recruitment of Fc-dependent effector functions, as well as identified with favorable hematology safety profile and robust pro-phagocytosis activity. (bmj.com)
  • Herein, we engineered CD19-CAR T cells to secrete an anti-CD47 single-chain variable fragment (scFv) and validated their function in enhancing antitumor efficacy, regulating T cells differentiation, modifying phagocytosis and polarization of macrophages by in vitro and in vivo researches. (bvsalud.org)
  • While macrophage phagocytosis is an immune defense mechanism against invading cellular organisms, cancer cells expressing the CD47 ligand send forward signals to repel this engulfment. (bvsalud.org)
  • Although low CD47-expressing cancer cells still allow phagocytosis, the reverse signaling delays the process, leading to incomplete digestion of the entrapped cells and subsequent tumor hybrid cell (THC) formation. (bvsalud.org)
  • Notably, CXCR4/CXCL12 cross-signal via the T and B cell receptors (TCR and BCR) and co-internalize with CD47, promoting tumor cell phagocytosis by macrophages in an anti-tumor immune process called ImmunoGenic Surrender (IGS). (unisr.it)
  • When tested intravenously in monkeys, LVs with high levels of CD47 were more resistant to phagocytosis and were less susceptible to detection by antigen-presenting cells than normal LVs were, the researchers reported. (international-biopharma.com)
  • In this manner mild reactivity of wild-type RBCs with macrophage phagocytic receptors is tolerated, whereas otherwise identical CD47-deficient RBCs are rapidly eliminated. (ashpublications.org)
  • This phenotype is at least partially due to a markedly increased rate of elimination of opsonized CD47 −/− compared to CD47 + RBCs. (ashpublications.org)
  • In vivo focusing on of CD47 poses challenging due to its higher level of manifestation on cells of hematopoietic source, including red blood cells (RBCs) and platelets. (nsdfu.org)
  • While irrelevant in xenotransplantation models where the recipients RBCs do not usually react with species-specific CD47 providers, this sink is definitely a crucial pharmacodynamic variable inside a syngeneic establishing (4, 7C11, 19). (nsdfu.org)
  • Fc-mediated opsonization also depletes RBCs, raising concerns that potential on-target anemia could result from the use of anti-CD47 agents. (ox.ac.uk)
  • CBCs were measured, and blood and BM samples were analyzed by flow cytometry for CD47 expression on RBCs and white blood cells (WBCs). (ox.ac.uk)
  • Results: Treatment with magrolimab+azacitidine resulted in tolerable anemia that correlated with rapid, near-complete loss of CD47 in RBCs but not WBCs. (ox.ac.uk)
  • Instead, this CD47 loss requires anti-CD47 cross-linking between RBCs and non-RBCs. (ox.ac.uk)
  • Clinical trials with existing CD47 neutralising antibodies have experienced severe side effects, including anaemia caused by the destruction of red blood cells (RBCs). (asiabiotech.com)
  • The Rh blood group antigens (MIM 111700) are associated with human erythrocyte membrane proteins of approximately 30 kD, the so-called Rh30 polypeptides. (novusbio.com)
  • Two of the proteins (ROR2 and CD47) involved in this study are expressed on the surface of LMS cells. (sarcomahelp.org)
  • Additionally, BMVs consist of considerable proteins, for example, original bacterial antigens and pathogen-associated molecular pattern components [ 5 ] . (encyclopedia.pub)
  • Other cell surface proteins, including CD326 (EpCAM), epithelial specific antigen, CD133, CD166, CD47, CD201, and ABCG2 have been reported as CSC markers for different BC subtypes and drug-resistant tumors ( 4 , 5 ). (life-science-alliance.org)
  • in the absence of CD47 mice show defects in host defense and β3 integrin-dependent ligand binding, migration, and cellular activation. (biolegend.com)
  • In the absence of CD47, mice show defects in host defense and beta 3 integrin-dependent ligand binding, migration, and cellular activation. (biolegend.com)
  • On binding with CD47, mediates cell-cell adhesion. (nih.gov)
  • CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. (abeomics.com)
  • Surface calreticulin activates macrophages and triggers dendritic cell maturation, promoting effective antigen presentation and therefore activating antitumor T cells. (bvsalud.org)
  • Following the co-internalization of CXCR4 and CD47 in tumor cells, macrophages phagocytose them and cross-present their antigens to the adaptive immune system, leading to tumor rejection in a fraction of mice. (unisr.it)
  • Anti-CD47 antibodies block this "don't eat me" signal sent by CD47 on cancer cells to phagocytic cells, restoring the phagocytic function of macrophages and other phagocytic cells, and therefore increasing anti-cancer immune responses. (asiabiotech.com)
  • Of note, anti-CD47 scFv secreting CAR T cells exert a more potent immune response following specific antigen stimulation compared with parental CAR T cells, characterized by more efficient degranulation and cytokine production with polyfunctionality. (bvsalud.org)
  • This study evaluated contemporary national-level trends and their relations with prostate-specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage-specific, delay-adjusted rates. (cdc.gov)
  • Loss of CD47 allows sustained proliferation of primary murine endothelial cells and enables these cells to spontaneously reprogram to form multipotent embryoid body-like clusters. (wikipedia.org)
  • Expression of several stem cell markers, including c-Myc, is elevated in CD47-null endothelial cells and a human T cell line lacking CD47. (wikipedia.org)
  • They are secreted by a wide array of cells, including cardiac myocytes, mature and progenitor endothelial cells, mesenchymal stem cells, immune cells like antigen-presenting cells (APCs), and malignant cells 5 , 6 . (bmrat.org)
  • Preclinical modeling studies were conducted with intact and Fc-deficient anti-mouse CD47 (MIAP410) and anti-human CD47 (magrolimab) antibodies in murine models, including C57BL/6J B-hSIRPA/hCD47 mice. (ox.ac.uk)
  • The company concluded that its investigational CD47 inhibitor was unlikely to demonstrate a survival benefit, compared with standard care, for patients enrolled in the phase III ENHANCE-2 trial. (aacrjournals.org)
  • the company also just ended codevelopment of I-Mab's lemzoparlimab, another CD47 inhibitor, besides recently dropping Harpoon Therapeutics' anti-BCMA trispecific T-cell engager, HPN217. (aacrjournals.org)
  • Using a layered double hydroxide nanosheet carrier, we co-deliver a T-type calcium channel inhibitor (TTA-Q6) and a CD47 inhibitor (RRX-001) into lung tumors. (bvsalud.org)
  • DSP107 targets CD47-overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to tumor antigen-specific activated T-cells. (pharmiweb.com)
  • CD47 has been proved to be a promising therapeutic target and is crucial in regulating macrophage function. (bvsalud.org)
  • However, these isoforms are highly conserved between mouse and man, suggesting an important role for the cytoplasmic domains in CD47 function. (wikipedia.org)
  • This facilitates interaction of SET with the newly translated cytoplasmic domains of CD47 and results in subsequent translocation of CD47 to the plasma membrane via activated RAC1 (ref. 5). (nih.gov)
  • CD47 is ubiquitously expressed in human cells and has been found to be overexpressed in many different tumor cells. (wikipedia.org)
  • Activation of CD47 with TSP-1 increases proliferation of human U-87 MG and U373 astrocytoma cells but not normal astrocytes. (wikipedia.org)
  • Additionally, CD47 blocking antibodies inhibit proliferation of unstimulated astrocytoma cells but not normal astrocytes. (wikipedia.org)
  • Though the exact mechanism is unclear, it is likely that CD47 promotes proliferation via the PI3K/Akt pathway in cancerous cells but not normal cells. (wikipedia.org)
  • Activation of CD47 with TSP-1 in wild-type cells inhibits proliferation and reduces expression of stem cell transcription factors. (wikipedia.org)
  • The activation of CD47 induces rapid apoptosis of T cells. (wikipedia.org)
  • Similarly, CD47 ligation rapidly induces apoptosis in B-cell chronic lymphocytic leukemia (CLL) cells. (wikipedia.org)
  • Tumor immunogenicity results from the processing, and subsequent presentation of tumor antigens released from dead or dying tumor cells on MHC molecules expressed on antigen-presenting cells (APC). (aacrjournals.org)
  • Engagement on T-cells by CD47 on antigen-presenting cells results in enhanced antigen-specific T-cell proliferation and costimulates T-cell activation. (nih.gov)
  • A) FACS binding curves of AK117 and Hu5F9-G4 to CD47 on raji cells. (bmj.com)
  • Daily doses of 200 g of A4 stained 50C60% of accessible CD47 on circulating hematopoietic cells (3, 4, 7, 10). (nsdfu.org)
  • Cross-reactivity with bovine cells of monoclonal antibodies submitted to the 6th International Workshop on Human Leukocyte Differentiation Antigens. (ox.ac.uk)
  • These were investigated further by two-colour immunofluorescence to compare the cellular expression of the antigen on cattle cells with that reported for the different CD antigens in humans. (ox.ac.uk)
  • Four of the MAb that belonged to CD23, CD39, CD47, and CDw149 stained bovine cells in a manner that indicated an almost identical cellular distribution of the antigen to that reported in humans. (ox.ac.uk)
  • In addition, CXCL12 and CXCR4 are involved in antigen recognition by T and B cells and in shaping the tumor microenvironment (TME), mainly towards dampening immune responses. (unisr.it)
  • Antigen-presenting cells (APCs) produce and release a broad spectrum of EVs involved in the pathogenesis of atherosclerosis. (bmrat.org)
  • Therefore, antigen-presenting cells (APCs) are able to recognize and absorb BMVs, and subsequently signaling pathways in immune cells are activated followed by specific immune responses. (encyclopedia.pub)
  • Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. (canadianinsider.com)
  • In a recent study, researchers from the Stanford University School of Medicine (USA) found that cells with surface antigen CD47 are extremely abundant in -atherosclerotic plaque, and that CD47-blocking antibodies reverse defects in efferocytosis, normalize the clearance of diseased vascular tissue and ameliorate atherosclerosis in multiple mouse models. (edu.pl)
  • Given the dose-limiting hematologic toxicity and antigen sink liability associated with current anti-CD47 antibodies in clinical development, Adagene has developed an anti-CD47 SAFEbody with precision masking for preferential binding on CD47 overexpressed on tumor versus normal cells. (adagene.com)
  • Binding of TSP-1 to CD47 influences several fundamental cellular functions including cell migration and adhesion, cell proliferation or apoptosis, and plays a role in the regulation of angiogenesis and inflammation. (wikipedia.org)
  • It is likely that intracellular and membrane-associated partners are crucial in determining the cellular response of CD47 signaling. (wikipedia.org)
  • Our preclinical studies with mouse models revealed that CD47 removal is mechanistically independent of previously described RBC antigen modulation mechanisms and cellular compartments. (ox.ac.uk)
  • Some functions, such as neutralization, mainly depend on interaction of the Fv domain ( Figure 1A ) with antigen and are therefore predominantly Fc domain independent. (frontiersin.org)
  • The CD47-targeted nanocarriers could be efficiently adsorbed to the surface of VECs in vitro, and their targeted distribution was evaluated in vivo. (edu.pl)
  • CD47 interacts with several membrane integrins, most commonly integrin αVβ3. (wikipedia.org)
  • These interactions result in CD47/integrin complexes that affect a range of cell functions including adhesion, spreading and migration. (wikipedia.org)
  • CD47 interacts with several membrane integrins, most commonly integrin avb3. (wikidoc.org)
  • Proceeds will be used for advancing the Company's next generation immuno-oncology drug candidates including the clinical development of the Company's lead product, DSP107, an anti-CD47 therapy for the treatment of solid tumors through a Phase I/II study and the preclinical advancement of additional pipeline projects. (pharmiweb.com)
  • Other cross-reacting MAb either recognized antigens already defined in cattle or antigens not yet clustered in humans. (ox.ac.uk)
  • Twelve subpanels of monoclonal antibodies (MAb) included within the 6th International Workshop on Human Leukocyte Differentiation Antigens (6th HLDA) were assayed for reactivity with bovine peripheral blood leukocytes. (ox.ac.uk)
  • CD47 is very broadly distributed on normal adult tissues. (dimabio.com)
  • The hybridoma-expressing mouse anti-human CD47 blocking mAb B6H1252 was purchased in the ATCC (clone B6H12.2, HB-9771). (ece-inhibitor.com)
  • CD47 ligation leads to cell death in many normal and tumor cell lines via apoptosis or autophagy. (wikipedia.org)
  • However, apoptosis was not observed following culture with other anti-CD47 antibodies. (wikipedia.org)
  • The apoptosis inducing function of CD47 appears to be dependent on activation of specific epitopes on the extracellular domain. (wikipedia.org)
  • Cyster and colleagues now demonstrate that the "self" molecule CD47 on erythrocytes critically restricts splenic DC activation. (amsterdamumc.org)
  • The Rh antigens appear to exist as a multisubunit complex of CD47 (MIM 601028), LW (MIM 111250), glycophorin B (MIM 111740), and play a critical role in the Rh50 glycoprotein. (novusbio.com)
  • Multiple Injections of an Anti-CD47 Nanobody Fail to Achieve Total Blockade of CD47 in the Tumor Microenvironment. (nsdfu.org)
  • CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. (novoprolabs.com)
  • Similarly, CD47 −/− C57BL/6 mice were much more sensitive than their wild-type counterparts to experimental passive AIHA induced by anti-RBC monoclonal antibodies. (ashpublications.org)
  • antigen sink. (ece-inhibitor.com)
  • This creates a substantial antigen sink that sequesters A4 from your tumor microenvironment (3, 4). (nsdfu.org)
  • To realize the full potential of anti-CD47 therapy for both hematologic and solid malignancies, the SAFEbody technology enables IgG1-mediated strong effector functions for potent tumor killing, while minimizing antigen sink and red blood cell (RBC) depletion with an approximately 8-fold prolonged half-life for convenient drug dosing and administration. (adagene.com)
  • Human peripheral blood lymphocytes were stained with anti-human CD47 (clone CC2C6) PE/Dazzle™ 594 (filled histogram) or mouse IgG1, κ PE/Dazzle™ 594 isotype control (open histogram). (biolegend.com)
  • We show here that virtually all CD47-deficient nonobese diabetic (NOD) mice spontaneously develop severe lethal autoimmune hemolytic anemia (AIHA) at 180 to 280 days of age, whereas none of the control CD47 + NOD mice develop lethal AIHA at least during the first year of life. (ashpublications.org)
  • Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis. (ajcr.us)
  • CD47 is also part of the Rh complex on erythrocytes. (biolegend.com)
  • Antigens, CD47" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (rush.edu)
  • Yu J, Ruan Q, Nie X. Synthesis and characterization of atherosclerotic target anti-CD47 functionalized by nano- polyelectrolyte complexes between chitosan and hyaluronic acid and in vivo and in vitro targeting experiments. (edu.pl)